Results 181 to 190 of about 46,788 (276)
ABSTRACT The goal of this prospective, single‐arm pilot study was to assess tolerability and clinical benefit for cats with histologically confirmed lymphocytic lymphoma/chronic inflammatory enteropathy complex (FLL/CIE) treated with low‐dose abdominal cavity radiation therapy (RT; 8 Gy total dose administered in four 2 Gy fractions).
Tracy L. Gieger+3 more
wiley +1 more source
Rituximab Induced Lichen Planus. [PDF]
Mannu A, Bala N, Das P, Sharma S.
europepmc +1 more source
First report of indolent cutaneous T‐cell lymphoma in a fennec fox (Vulpes zerda)
A 10‐year‐old fennec fox (Vulpes zerda) was presented for multifocal regions of chronic alopecia and crusting. Cutaneous lymphocytosis was diagnosed through histopathological examination and immunohistochemical investigation. Clonal rearrangement of the T‐cell receptor gamma locus supports that lymphocytosis in this case is an indolent lymphoma ...
Kristen L. Shekelle+5 more
wiley +1 more source
Leukemia Cell Surface Antigen Modulation Induced By Dual CD19/CD20 Chimeric Antigen Receptor (CAR)-T Cells [PDF]
Darong Wu+7 more
openaire +2 more sources
Hyperkeratosis of (a) the footpads and (b) the nasal planum. ABSTRACT Background Canine leishmaniosis (CanL) due to Leishmania infantum remains common, and veterinarians do not always follow scientifically sound approaches for diagnosis, treatment and prevention. Objectives To provide consensus guidelines for diagnosis and evidence‐based guidelines for
Manolis N. Saridomichelakis+9 more
wiley +1 more source
Immunotherapy in chronic lymphocytic leukemia: advances and challenges. [PDF]
Gao P, Zhang Y, Ma J, Zhang Y.
europepmc +1 more source
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah+2 more
wiley +1 more source
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches
Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi+8 more
wiley +1 more source
Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20. [PDF]
Cecchi N+6 more
europepmc +1 more source
Lymphocyte subsets as surrogate markers in antiretroviral therapy. [PDF]
Bogner, Johannes R.+1 more
core +1 more source